Disease · MONDO_0005186
Comparisons in its trials91
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 91
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CPP-109 Vigabatrin Tablets vs Matching Placebo: Abstinence | 5 of 103 | 9 of 104 | 207 | NCT01281202 | Trial comparisons |
| CPP-109 Vigabatrin Tablets vs Placebo: serious adverse events | 6 of 103 | 3 of 104 | 207 | NCT01281202 | Trial comparisons |
| CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablets: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment. | 7 of 92 | 5 of 94 | 186 | NCT00611130 | Trial comparisons |
| CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablet: serious adverse events | 6 of 92 | 0 of 94 | 186 | NCT00611130 | Trial comparisons |
| Nepicastat vs Placebo: Reduction in Use (Weeks 1 - 11) | 13 of 90 | 20 of 89 | 179 | NCT01704196 | Trial comparisons |
| Nepicastat vs Placebo: Abstinence (Weeks 10 - 11) | 4 of 90 | 7 of 89 | 179 | NCT01704196 | Trial comparisons |
| Nepicastat vs Placebo: serious adverse events | 8 of 90 | 2 of 89 | 179 | NCT01704196 | Trial comparisons |
| Topiramate vs Placebo: deaths from any cause | 0 of 83 | 0 of 87 | 170 | NCT00167245 | Trial comparisons |
| Topiramate vs Placebo: serious adverse events | 0 of 83 | 0 of 87 | 170 | NCT00167245 | Trial comparisons |
Varenicline vs Placebo: Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the Chantix Group Versus the Placebo Group Comparator During the Last Three Weeks of the Trial | 6 of 80 | 7 of 76 | 156 | NCT01680887 | Trial comparisons |
| Varenicline vs Placebo: deaths from any cause | 0 of 80 | 0 of 76 | 156 | NCT01680887 | Trial comparisons |
| Varenicline vs Placebo: serious adverse events | 6 of 80 | 6 of 76 | 156 | NCT01680887 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: Three Weeks of Cocaine Abstinence at End of Study | 9 of 64 | 0 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: Any Three Consecutive Weeks of Abstinence During Study | 14 of 64 | 4 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: deaths from any cause | 0 of 64 | 0 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: serious adverse events | 2 of 64 | 2 of 63 | 127 | NCT01811940 | Trial comparisons |
| Biperiden vs Placebo: deaths from any cause | 0 of 56 | 0 of 55 | 111 | NCT01251393 | Trial comparisons |
| Biperiden vs Placebo: serious adverse events | 0 of 56 | 0 of 55 | 111 | NCT01251393 | Trial comparisons |
| Ondansetron vs Placebo: deaths from any cause | 0 of 53 | 0 of 55 | 108 | NCT00689572 | Trial comparisons |
| Ondansetron vs Placebo: serious adverse events | 1 of 53 | 1 of 55 | 108 | NCT00689572 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005186/comparisons